The Center for Innovation in Medicine is an NGO based in Bucharest, Romania, focused on the innovation in healthcare that aims to shorten the time between the emergence of innovations and their application for patients benefit in Romania and elsewhere. We develop programs to educate, inform and engage all audiences about innovation in medicine in an attempt to create a friendly environment for early adoption of innovative technologies, ideas, products and services, serving as an independent platform for informed dialogue between all stakeholders in the field of omics medicine, personalised (precision) medicine, digital health, data oncology, immune-oncology, cancer research, biotechnology, systems biology and other hot scientific topics.
On September 10th, DG SANTE organized a webinar on the priorities, strategic orientations and the needs to be addressed through the EU4Health annual work programmes, building on the outcomes of the targeted consultation organized during the summer of 2021.
Disease prevention and health promotion represent the most urgent needs to be addressed in the next programming of EU4Health, starting with 2022, according to the inputs from diverse stakeholders (NGOs, associations, businesses, Member States’ policymakers, patients’ organizations).
Around 20% of all premature deaths (below the age of 65) in the EU are caused by CVD. CVDs are caused by so-called modifiable or non-modifiable (inherited, genetic) risk factors. The world’s most common and non-modifiable CVD risk factor is Familial Hypercholesterolemia (FH). Less than 10% of those born with FH, are diagnosed and adequately treated, leading to heart attacks, strokes, heart disease and deaths, early in life, even as early as 4 years of age.
During the webinar, Dr. Marius Geantă, President of the Centre for Innovation in Medicine and co-chair of the Scientific and Public Health Advisory Committee at FH Europe, presented a proposal on the implementation of evidence-based paediatric screening and early detection programs for FH at the EU level. More details.
Today (9th of September 2021) The Centre for Innovation in Medicine, as a member of the ECO Inequalities Network, is pleased to announce the launch of “Time to Act” campaign in Romania. Our president, Dr. Marius Geantă is a speaker during the event and a member of the Steering Committee of the Inequalities Network.
- An estimated one million Cancer cases could be undiagnosed in Europe
- An estimated 100 million Cancer screening tests were not performed in Europe during the pandemic, leading to later stage diagnoses and decreased overall survival
- Up to 1 in 2 people with potential cancer symptoms were not urgently referred for diagnosis
- 1 in every 5 cancer patients in Europe is currently still not receiving the surgical or chemotherapy treatment they need
The “Big C” won’t wait for the Covid-19 pandemic to be over and neither should Romania or any European state. Follow this link for all the information about the event.
The message of Dr. Marius Geantă: “Inequalities at EU level are the reason I joined ECO last year. We have reached this point because over time we have continued to do things the same way and, implicitly, if we continue in the same way, in the best case scenario, inequalities will persist. But as innovation develops, inequalities will certainly increase.
- The fight against cancer must be waged by all actors who have something to say in the field of cancer, including the NGOs;
- Financing is not a problem, but we need to know how to spend that money, there must be quality control systems;
- We must also be honest, admit that we have something to learn – the idea of promoting twinning and teaming projects makes a lot of sense;
- The use of data in the European Data Health Space is very important;
- And in order to have access to these innovations, we need to understand them and we need targeted educational projects.”
Marius Geantă, MD, president of Centre for Innovation in Medicine, was a speaker on the 2nd day of the event: “Technology has increased the resolution at the society level. 4K resolution, many times AI-enabled, is the gold standard in many of our daily activities: watching movies, football matches, playing video games, videoconferences and so on. But can we say the same about health, about the health system? Probably not. There are diseases, hospitals, medical specialties, or even cities or countries where health or medicine could not be considered yet as high definition or 4K medicine/health. The data either does not exist, is not collected and integrated, or is used sub-optimally, or is used incorrectly or is impossible to use. An analysis of the determinants of health shows us how great the potential of health data and non-biased AI is and how little we use from what data we already produce or could produce, as a society”.
More details, here.
Dr. Marius Geantă is a pioneer in the field of personalised medicine in Romania and Central Eastern Europe. A vast majority of his projects involve precision and personalised medicine in oncology. His joining of the FH Europe – The European FH Patient Network comes at a time when the scientific knowledge accumulated until present facilitates the application of prevention in cardiology through genetic testing programs. And Familial Hypercholesterolemia has the potential to become the engine that drives these efforts forward.
Innovation must be a factor that unites the Eastern and Western Europe by reducing the inequalities between member states when it comes to prevention, screening, early diagnosis, treatment or palliative care.
Levels of health inequality between countries and regions with respect to cancer prevention, control, access to treatment and survival can no longer be ignored. Inequalities also occur within countries, between regions, and between social groups.
The Centre for Innovation in Medicine organised the fifth edition of the Conference on Personalised Medicine. It took place virtually via Zoom. The Conference was planned in the context of the European Biotechnology Week 2020. EuropaBio was the event partner. The event gathered representatives of the authorities, academia, professional societies, patient associations and industry. Our main sessions evolved around discussions on building resilient healthcare systems.